References
- Carvalho M, Martins AP, Sepodes B. Hurdles in gene therapy regulatory approval: a retrospective analysis of European marketing authorization applications. Drug Discov Today. 2019 Mar;24(3):823–828.
- Rousseau CF, Mačiulaitis R, Śladowski D, et al. Cell and gene therapies: European view on challenges in translation and how to address them. Front Med (Lausanne). 2018;5:158.
- Regulation (EC) No 1394/2007 of the European Parliament and of the Council of 13 November 2007 on advanced therapy medicinal products and amending Directive 2001/83/EC and Regulation (EC) No 726/2004. OJ L 324, 10.12.2007, p. 121–137.
- Carvalho M, Sepodes B, Martins AP. Regulatory and scientific advancements in gene therapy: state-of-the-art of clinical applications and of the supporting European regulatory framework. Front Med (Lausanne). 2017 Oct 26;4:182. eCollection 2017.
- European Medicines Agency. Advanced therapy medicinal products: overview. [cited 2019 May 15]. Available from: https://www.ema.europa.eu/en/human-regulatory/overview/advanced-therapy-medicinal-products-overview
- European Medicines Agency. Summaries of scientific recommendations on classification of advanced therapy medicinal products. [cited 2019 May 15]. Available from: https://www.ema.europa.eu/en/human-regulatory/marketing-authorisation/advanced-therapies/advanced-therapy-classification/summaries-scientific-recommendations-classification-advanced-therapy-medicinal-products
- European Medicines Agency. European public assessment reports (EPAR). [cited 2019 May 15]. Available from: https://www.ema.europa.eu/en/medicines/download-medicine-data#european-public-assessment-reports-(epar)-section
- Iskrov G, Miteva-Katrandzhieva T, Stefanov R. Challenges to orphan drugs access in Eastern Europe: the case of Bulgaria. Health Policy. 2012 Nov;108(1):10–18.
- European Medicines Agency. Benefit-risk methodology. [cited 2019 May 15]. Available from: https://www.ema.europa.eu/en/about-us/support-research/benefit-risk-methodology
- Jönsson B, Hampson G, Michaels J, et al. Advanced therapy medicinal products and health technology assessment principles and practices for value-based and sustainable healthcare. Eur J Health Econ. 2019 Apr;20(3):427–438.
- Pearson S Early experience with health technology assessment of gene therapies in the United States: pricing and paying for cures. [cited 2019 May 15]. Available from: https://www.ohe.org/publications/early-experience-health-technology-assessment-gene-therapies-united-states-pricing-and
- Hampson G, Towse A, Pearson SD, et al. Gene therapy: evidence, value and affordability in the US health care system. J Comp Eff Res. 2018 Jan;7(1):15–28.
- Iskrov G, Stefanov R. Post-marketing access to orphan drugs: a critical analysis of health technology assessment and reimbursement decision-making considerations. Orphan Drugs Res Rev. 2014 Jan;4:1–9.
- Sinclair A, Islam S, Jones S. Gene therapy: an overview of approved and pipeline technologies. Ottawa: CADTH; 2018 Mar 1. In: CADTH issues in emerging health technologies. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2016. p. 171. [cited 15 May 2019]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK538378/
- Abou-El-Enein M, Elsanhoury A, Reinke P. Overcoming challenges facing advanced therapies in the EU market. Cell Stem Cell. 2016 Sep 1; 19(3):293–297.
- Towse A, Mauskopf JA. Affordability of new technologies: the next frontier. Value Health. 2018 Mar;21(3):249–251.
- Directive 2001/83/EC of the European Parliament and of the Council of 6 November 2001 on the Community code relating to medicinal products for human use. OJ L 311, 28.11.2001, p. 67–128.
- Dupont AG, Van Wilder PB. Access to orphan drugs despite poor quality of clinical evidence. Br J Clin Pharmacol. 2011 Apr;71(4):488–496.
- Woolacott N, Corbett M, Jones-Diette J, et al. Methodological challenges for the evaluation of clinical effectiveness in the context of accelerated regulatory approval: an overview. J Clin Epidemiol. 2017 Oct;90:108–118.
- Wallach JD, Ross JS, Naci H. The US food and drug administration’s expedited approval programs: evidentiary standards, regulatory trade-offs, and potential improvements. Clin Trials. 2018 Jun;15(3):219–229.
- Detela G, Lodge A. EU regulatory pathways for ATMPs: standard, accelerated and adaptive pathways to marketing authorisation. Mol Ther Methods Clin Dev. 2019 Jan;29(13):205–232.
- Brenner MK, Gottschalk S, Leen AM, et al. Is cancer gene therapy an empty suit? Lancet Oncol. 2013 Oct;14(11):e447–e456.
- Schaffer SK, Messner D, Mestre-Ferrandiz J, et al. Paying for cures: perspectives on solutions to the “Affordability Issue”. Value Health. 2018 Mar;21(3):276–279.
- Lakdawalla DN, Doshi JA, Garrison LP Jr, et al. Defining elements of value in health care-a health economics approach: an ISPOR special task force report [3]. Value Health. 2018 Feb;21(2):131–139.
- Husereau D, Henshall C, Sampietro-Colom L, et al. Changing health technology assessment paradigms? Int J Technol Assess Health Care. 2016 Jan;32(4):191–199.
- Wittenberg E, James LP, Prosser LA. Spillover effects on caregivers’ and family members’ utility: a systematic review of the literature. Pharmacoeconomics. 2019 Apr;37(4):475–499.
- Garrison LP, Jackson T, Paul D, et al. Value-based pricing for emerging gene therapies: the economic case for a higher cost-effectiveness threshold. J Manag Care Spec Pharm. 2019 Jul;25(7):793–799.
- Drummond MF, Neumann PJ, Sullivan SD, et al. Analytic considerations in applying a general economic evaluation reference case to gene therapy. Value Health. 2019 Jun;22(6):661–668.
- Husereau D. How do we value a cure? Expert Rev Pharmacoecon Outcomes Res. 2015;15(4):551–555.
- Pierce GF, Coffin D; Members of the WFH Gene Therapy Round Table Program Committee and Organizing Committee. The 1st WFH gene therapy round table: understanding the landscape and challenges of gene therapy for haemophilia around the world. Haemophilia. 2019 Mar; 25(2):189–194.
- Iskrov G, Greenberg D, Yakimov I, et al. What is the value of innovative pharmaceutical therapies in oncology and hematology? A willingness-to-pay study in Bulgaria. Value Health Reg Issues. 2019 May 17. pii: S2212-1099(19)30059-7. [Epub ahead of print]. doi: 10.1016/j.vhri.2019.03.005.
- Schlander M. The use of cost-effectiveness by the National Institute for Health and Clinical Excellence (NICE): no(t yet an) exemplar of a deliberative process. J Med Ethics. 2008;34(7):534–539.
- Eichler HG, Kong SX, Gerth WC, et al. Use of cost-effectiveness analysis in health-care resource allocation decision-making: how are cost-effectiveness thresholds expected to emerge? Value Health. 2004;7(5):518–528.
- Faulkner E, Spinner DS, Ringo M, et al. Are global health systems ready for transformative therapies? Value Health. 2019 Jun;22(6):627–641.
- Kent A, Spink J. Will rising prices and budget constraints prevent patients from accessing novel gene therapies? Gene Ther. 2017 Sep;24(9):542–543.
- Quinn C, Young C, Thomas J, et al. Estimating the clinical pipeline of cell and gene therapies and their potential economic impact on the US healthcare system. Value Health. 2019 Jun;22(6):621–626.
- Carlson JJ, Chen S, Garrison LP Jr. Performance-based risk-sharing arrangements: an updated international review. Pharmacoeconomics. 2017 Oct;35(10):1063–1072.
- Scavone C, Di Mauro G, Mascolo A, et al. The new paradigms in clinical research: from early access programs to the novel therapeutic approaches for unmet medical needs. Front Pharmacol. 2019 Feb 13;10:111. eCollection 2019.
- Hampson G, Towse A, Dreitlein WB, et al. Real-world evidence for coverage decisions: opportunities and challenges. J Comp Eff Res. 2018 Dec;7(12):1133–1143.
- Jørgensen J, Mungapen L, Kefalas P. Data collection infrastructure for patient outcomes in the UK - opportunities and challenges for cell and gene therapies launching. J Mark Access Health Policy. 2019 Feb 4;7(1):1573164.
- Salzman R, Cook F, Hunt T, et al. Addressing the value of gene therapy and enhancing patient access to transformative treatments. Mol Ther. 2018 Dec 5;26(12):2717–2726.
- Friedmann T. Gene therapy for spinomuscular atrophy: a biomedical advance, a missed opportunity for more equitable drug pricing. Gene Ther. 2017 Sep;24(9):503–505.
- European Medicines Agency. Medicines under additional monitoring. [cited 2019 May 15]. Available from: https://www.ema.europa.eu/en/human-regulatory/post-authorisation/pharmacovigilance/medicines-under-additional-monitoring
- European Medicines Agency. Conditional marketing authorisation. [cited 2019 May 15]. Available from: https://www.ema.europa.eu/en/human-regulatory/marketing-authorisation/conditional-marketing-authorisation
- Crisafulli S, Sultana J, Ingrasciotta Y, et al. Role of healthcare databases and registries for surveillance of orphan drugs in the real-world setting: the Italian case study. Expert Opin Drug Saf. 2019 Jun;18(6):497–509.
- Yeung K, Suh K, Garrison LP Jr, et al. Defining and managing high-priced cures: healthcare payers’ opinions. Value Health. 2019 Jun;22(6):648–655.
- Pejcic AV, Iskrov G, Jakovljevic MM, et al. Access to orphan drugs - comparison across Balkan countries. Health Policy. 2018 Jun;122(6):583–589.
- Moliner AM, Waligora J. The European union policy in the field of rare diseases. Adv Exp Med Biol. 2017;1031:561–587.
- Beneluxa initiative [Internet]. [ cited 2019 Aug 29]. Available from: www.beneluxa.org
- Henrard S, Arickx F. Negotiating prices of drugs for rare diseases. Bull World Health Organ. 2016 Oct 1;94(10):779–781.